The Cardiac Conduction and Contractility Complications of Methamphetamine Use and the Relationship to Psychiatric Comorbidity: A Systematic Review

Author(s): Sarah Baker*, David Castle*

Journal Name: Current Psychiatry Research and Reviews
Formerly: Current Psychiatry Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Methamphetamine has the potential to produce more severe short and long term effects than typical amphetamines due to the drug’s increased purity. The cardiovascular consequences compromise a large proportion of the drug’s mortality. Previous reviews have not examined these complications in relation to psychiatric patients who have high rates of substance use and physical comorbidity.

Methods: Ovid Medline, Embase, Emcare, PsycINFO, CINAHL, and Cochrane were systematically searched in English until November 2017. Data were coded according to study design, sample size, demographics, medical and psychiatric comorbidity, electrocardiograph abnormalities, echocardiograph parameters, illness severity, treatment, and outcome on follow up.

Results: The 11 included studies were predominantly case series conducted in the USA. Males were more likely to use methamphetamine and be associated with global systolic dysfunction. The mean age was lower for those with methamphetamine-related cardiovascular complications. QTc interval prolongation was the most frequent electrocardiograph abnormality. Continued methamphetamine use was associated with persistently impaired ventricular function, whilst discontinuation led to remodeling and improved ejection fraction. Only one study referenced psychiatric comorbidity or dual diagnosis.

Conclusion: This review describes the range of variables related to methamphetamine associated arrhythmias and cardiomyopathies. Early detection of methamphetamine use and the subsequent cardiac complications is important, especially in a psychiatric cohort where physical illness is more commonly neglected. The monitoring of electrocardiographs in methamphetamine users is also crucial. Future research is needed to allow for appropriate recommendations in managing the harmful impacts of methamphetamine use in this population.

Keywords: Cardiomyopathy, arrhythmia, methamphetamine, psychiatry, electrocardiograph, echocardiograph.

[1]
United Nations Office on Drugs and Crime World drug report 2017.https://www.unodc.org/wdr2017/index.html(accessed February 2018)..
[2]
Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2016.https://www.aihw.gov.au/getmedia/15db8c15-7062-4cde-bfa4-3c2079f30af3/21028a.pdf.aspx?inline=true
[3]
Paratz ED, Cunningham NJ, MacIsaac AI. The Cardiac Complications of Methamphetamines. Heart Lung Circ 2016; 25(4): 325-32.
[http://dx.doi.org/10.1016/j.hlc.2015.10.019] [PMID: 26706652]
[4]
[5]
Minichino A, Bersani FS, Calò WK, et al. Smoking behaviour and mental health disorders-mutual influences and implications for therapy. Int J Environ Res Public Health 2013; 10(10): 4790-811.
[http://dx.doi.org/10.3390/ijerph10104790] [PMID: 24157506]
[6]
Robson D, Keen S, Mauro P. Physical health and dual diagnosis. Adv Dual Diagn 2008; 1(1): 27.
[7]
Pasic J, Russo JE, Ries RK, Roy-Byrne PP. Methamphetamine users in the psychiatric emergency services: a case-control study. Am J Drug Alcohol Abuse 2007; 33(5): 675-86.
[http://dx.doi.org/10.1080/00952990701522732] [PMID: 17891660]
[8]
Szuster RR. Methamphetamine in psychiatric emergencies. Hawaii Med J 1990; 49(10): 389-91.
[PMID: 2272810]
[9]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7)e1000097
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[10]
Critical Appraisal Skills Program (CASP). CASP Appraisal Checklist Available at:https://casp-uk.net/casp-tools-checklists/
[11]
Joanaa Briggs Istitute. 2017.Critical Appraisal Tools Available at:http://joannabriggs.org/research/critical-appraisal-tools.html
[12]
Kmet LM, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR) 2004. Available from:http://www.ihe.ca/advanced-search/standard-quality-assessment-criteria-for-evaluating-primary-research-papers-from-a-variety-of-fields
[13]
Ito H, Yeo KK, Wijetunga M, Seto TB, Tay K, Schatz IJ. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol 2009; 32(6): E18-22.
[http://dx.doi.org/10.1002/clc.20367] [PMID: 19330818]
[14]
Sliman S, Waalen J, Shaw D. Methamphetamine-associated congestive heart failure: increasing prevalence and relationship of clinical outcomes to continued use or abstinence. Cardiovasc Toxicol 2016; 16(4): 381-9.
[http://dx.doi.org/10.1007/s12012-015-9350-y] [PMID: 26661075]
[15]
Neeki MM, Kulczycki M, Toy J, et al. Frequency of methamphetamine use as a major contributor toward the severity of cardiomyopathy in adults ≤50 years. Am J Cardiol 2016; 118(4): 585-9.
[http://dx.doi.org/10.1016/j.amjcard.2016.05.057] [PMID: 27374605]
[16]
Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med 2007; 120(2): 165-71.
[http://dx.doi.org/10.1016/j.amjmed.2006.01.024] [PMID: 17275458]
[17]
Mau MK, Asao K, Efird J, et al. Risk factors associated with methamphetamine use and heart failure among native Hawaiians and other Pacific Island peoples. Vasc Health Risk Manag 2009; 5(1): 45-52.
[PMID: 19436660]
[18]
Paratz ED, Zhao J, Sherwen AK, Scarlato R-M, MacIsaac AI. Is an abnormal ECG just the tip of the ice-berg? Examining the utility of electrocardiography in detecting methamphetamine-induced cardiac pathology. Heart Lung Circ 2017; 26(7): 684-9.
[http://dx.doi.org/10.1016/j.hlc.2016.11.005] [PMID: 28110851]
[19]
Voskoboinik A, Ihle JF, Bloom JE, Kaye DM. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J 2016; 46(6): 723-7.
[http://dx.doi.org/10.1111/imj.13050] [PMID: 26929061]
[20]
Schürer S, Klingel K, Sandri M, et al. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Fail 2017; 5(6): 435-45.
[http://dx.doi.org/10.1016/j.jchf.2017.02.017] [PMID: 28571597]
[21]
Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction 2007; 102: 70-5.
[http://dx.doi.org/10.1111/j.1360-0443.2006.01776.x] [PMID: 17493055]
[22]
Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol 2003; 41(7): 981-6.
[http://dx.doi.org/10.1081/CLT-120026521] [PMID: 14705845]
[23]
Hawley LA, Auten JD, Matteucci MJ, et al. Cardiac complications of adult methamphetamine exposures. J Emerg Med 2013; 45(6): 821-7.
[http://dx.doi.org/10.1016/j.jemermed.2013.04.061] [PMID: 24054881]
[24]
Cooper J, Mancuso SG, Borland R, Slade T, Galletly C, Castle D. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry 2012; 46(9): 851-63.
[http://dx.doi.org/10.1177/0004867412449876] [PMID: 22645396]
[25]
Foley DL, Mackinnon A, Watts GF, et al. Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. PLoS One 2013; 8(12)e82606
[http://dx.doi.org/10.1371/journal.pone.0082606] [PMID: 24367528]
[26]
Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72(12): 1172-81.
[http://dx.doi.org/10.1001/jamapsychiatry.2015.1737] [PMID: 26509694]
[27]
Thornicroft G. Physical health disparities and mental illness: the scandal of premature mortality. Br J Psychiatry 2011; 199(6): 441-2.
[http://dx.doi.org/10.1192/bjp.bp.111.092718] [PMID: 22130744]
[28]
Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11): 1774-82.
[http://dx.doi.org/10.1176/appi.ajp.158.11.1774] [PMID: 11691681]
[29]
Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360(3): 225-35.
[http://dx.doi.org/10.1056/NEJMoa0806994] [PMID: 19144938]
[30]
Cotchett A, Higgind D. Dual Diagnosis Policy 2017. Available at:http://intranet/Policies/Mental Health Adult Policies/Dual Diagnosis Policy.pdf
[31]
Dzudie A, Kengne AP, Thienemann F, Sliwa K. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. BMJ Open 2014; 4(7)e004843
[http://dx.doi.org/10.1136/bmjopen-2014-004843] [PMID: 25011987]
[32]
Kurowski V, Kaiser A, von Hof K, et al. Apical and midventricular transient left ventricular dysfunction syndrome (tako-tsubo cardiomyopathy): frequency, mechanisms, and prognosis. Chest 2007; 132(3): 809-16.
[http://dx.doi.org/10.1378/chest.07-0608] [PMID: 17573507]
[33]
Eshtehardi P, Koestner SC, Adorjan P, et al. Transient apical ballooning syndrome--clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss population. Int J Cardiol 2009; 135(3): 370-5.
[http://dx.doi.org/10.1016/j.ijcard.2008.03.088] [PMID: 18599137]
[34]
Kaye S, McKetin R. Cardiotoxicity associated with methamphetamine use and signs of cardiovascular pathology among methamphetamine users 2005.Available at: https://ezp.lib.unimelb.edu.au/login?url= https://search.ebscohost.com/login.aspx?direct=true&db=edsdru& AN=edsdru.B1DFB1F&site=eds-live&scope=site
[35]
Darke S, Duflou J, Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: A national study. Drug Alcohol Depend 2017; 179: 174-9.
[http://dx.doi.org/10.1016/j.drugalcdep.2017.07.001] [PMID: 28787694]
[36]
Sallee BN, Nazir MR, Verda L. Reversible methamphetamine-associated cardiomyopathy (MAC). J Gen Intern Med 2017; 32(2): S582-3.
[37]
DE Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10(1): 52-77.
[http://dx.doi.org/10.1002/j.2051-5545.2011.tb00014.x] [PMID: 21379357]
[38]
Chehab O, Ioannou A, Sawhney A, Rice A, Dubrey S. Reverse takotsubo cardiomyopathy and cardiogenic shock associated with methamphetamine consumption. J Emerg Med 2017; 53(5): e81-3.
[http://dx.doi.org/10.1016/j.jemermed.2017.06.027] [PMID: 28916123]
[39]
Devkota AR, Dufrense A, Parajuli P. Acute reversible cardiomyopathy due to methamphetamine overdose. Br J Med Pract 2015; 8(4): 32-4.
[40]
Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265(9): 1152-4.
[http://dx.doi.org/10.1001/jama.1991.03460090100040] [PMID: 1996001]
[41]
Li J, Li J, Chen Y, et al. Methamphetamine use associated with monomorphic ventricular tachycardia. J Addict Med 2014; 8(6): 470-3.
[http://dx.doi.org/10.1097/ADM.0000000000000069] [PMID: 25230370]
[42]
Kumar S, Sharma R, Kalman JM. Unmasking of familial long QT syndrome type 2 with crystal methamphetamine exposure. Heart Rhythm 2014; 11(10): 1836-8.
[http://dx.doi.org/10.1016/j.hrthm.2014.05.034] [PMID: 24882508]
[43]
Lopez JE, Yeo K, Caputo G, Buonocore M, Schaefer S. Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2009; 11(1): 46.
[http://dx.doi.org/10.1186/1532-429X-11-46] [PMID: 19906310]
[44]
Nishida N, Ikeda N, Kudo K, Esaki R. Sudden unexpected death of a methamphetamine abuser with cardiopulmonary abnormalities: a case report. Med Sci Law 2003; 43(3): 267-71.
[http://dx.doi.org/10.1258/rsmmsl.43.3.267] [PMID: 12899434]
[45]
Sadeghi R, Agin K, Taherkhani M, et al. Report of methamphetamine use and cardiomyopathy in three patients. Daru 2012; 20(1): 20.
[http://dx.doi.org/10.1186/2008-2231-20-20] [PMID: 23351936]
[46]
Srikanth S, Barua R, Ambrose J. Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology 2008; 109(3): 188-92.
[http://dx.doi.org/10.1159/000106681] [PMID: 17728543]
[47]
Stokes MB, Fernando H, Taylor AJ. Cardiogenic shock secondary to methamphetamine induced cardiomyopathy requiring veno-arterial extra-corporeal membrane oxygenation. Int J Cardiol 2016; 207: 134-5.
[http://dx.doi.org/10.1016/j.ijcard.2016.01.077] [PMID: 26800137]
[48]
Tran A, Grimaldi L, Shah A, Menon S, Levine M. Inverse takotsubo cardiomyopathy after methamphetamine use. J Med Toxicol 2014; 10(1): 97.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [5 - 19]
Pages: 15
DOI: 10.2174/2666082216666200226102417
Price: $65

Article Metrics

PDF: 9
HTML: 1
EPUB: 1